Detalhe da pesquisa
1.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Ann Hematol
; 102(3): 547-561, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36695874
2.
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Ann Hematol
; 100(9): 2387-2398, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34232360
3.
Correction to: Allogeneic hematopoietic stem cell transplantation improves longterm outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Ann Hematol
; 100(11): 2877-2878, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34529106